Myelodysplastic syndrome, which refers to a group of blood disorders, affects an estimated 60,000 people in the U.S. The abnormal or malignant precursor cells in the bone marrow proliferates resulting in a disordered and ineffective production of the myeloid lineage, which includes red blood cells, white blood cells and platelets in patients with myelodysplastic syndrome (MDS). Reblozyl, Inqovi, Vidaza, Dacogen, and Revlimid are some of the FDA-approved treatments for MDS.
The stock we are bringing to your attention is that of a late-stage clinical biopharmaceutical company developing a drug for lower risk myelodysplastic syndromes - Geron Corp. (GERN).
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.